Form 4 for TCRX TScan Therapeutics, Inc.
Accepted 2024-08-27 00:00:00 ET · period of report 2024-08-23 · accession 0000950170-24-101161 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-27 | 2024-08-23 | TCRX | ZDRAVESKI ZORAN | See Remarks | S - Sale+OE | $5.78 | -164.7K | 4,716 | -97% | -$951.9K |
| DM | 2024-08-27 | 2024-08-23 | TCRX | ZDRAVESKI ZORAN | See Remarks | M - OptEx | $3.38 | +157.2K | 67.1K | New | +$531.5K |
| DM | 2024-08-27 | 2024-08-23 | TCRX | ZDRAVESKI ZORAN | See Remarks | M - OptEx | $0.00 | -157.2K | 21.9K | -88% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Voting Common Stock | 2024-08-23 | S | D | 164,686 | $5.78 | 4,716 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.56 to $5.91, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request. |
| 2 | Common | Voting Common Stock | 2024-08-23 | M | A | 64,166 | $2.49 | 169,402 | D | — | — | |
| 3 | Common | Voting Common Stock | 2024-08-23 | M | A | 13,125 | $1.81 | 105,236 | D | — | — | |
| 4 | Common | Voting Common Stock | 2024-08-23 | M | A | 25,000 | $3.27 | 92,111 | D | — | — | |
| 5 | Common | Voting Common Stock | 2024-08-23 | M | A | 54,895 | $4.85 | 67,111 | D | — | — | (F1) Includes 7,500 shares of Voting Common Stock acquired under the TScan Therapeutics, Inc. 2021 Employee Stock Purchase Plan on December 31, 2022. |
| 6 | Derivative | Stock Option (Right to Buy) | 2024-08-23 | M | D | 64,166 | $0.00 | 365,834 | D | $2.49 · — to 2033-06-12 | 64,166 Voting Common Stock | (F6) 220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023. |
| 7 | Derivative | Stock Option (Right to Buy) | 2024-08-23 | M | D | 25,000 | $0.00 | 25,000 | D | $3.27 · — to 2032-07-24 | 25,000 Voting Common Stock | (F4) The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. |
| 8 | Derivative | Stock Option (Right to Buy) | 2024-08-23 | M | D | 54,895 | $0.00 | 30,105 | D | $4.85 · — to 2032-01-17 | 54,895 Voting Common Stock | (F3) The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. |
| 9 | Derivative | Stock Option (Right to Buy) | 2024-08-23 | M | D | 13,125 | $0.00 | 21,875 | D | $1.81 · — to 2033-02-01 | 13,125 Voting Common Stock | (F5) The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter. |